Cipla
-
October 23, 2020, Friday
USFDA approves Remdesivir as first Covid-19 therapy amid WHO reservations
Approval unlikely to increase prices immediately as Gilead has said licenses are royalty-free until the end of the health ...
-
October 16, 2020, Friday
Chris Wood hikes allocation to Indian equities; raises stake in HDFC
Among Indian stocks, besides HDFC, Wood also holds Reliance Industries (RIL), Maruti Suzuki, SBI Life Insurance, DLF and Cipla
-
October 13, 2020, Tuesday
Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high
In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma ...
-
October 11, 2020, Sunday
Smaller pharma firms post faster domestic sales growth in September
Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, ...
-
October 08, 2020, Thursday
Cipla up 5% on hope of healthy Q2 performance; rallies 56% in six months
The company is expected to report strong growth in the recently concluded quarter, driven by the portfolio of drugs it ...
-
September 25, 2020, Friday
Cipla shares gain 5% after USFDA okays capsules; m-cap rises by Rs 3,021 cr
The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.
-
September 25, 2020, Friday
Cipla surges 5% on USFDA approval for dimethyl fumarate DR capsules
The drug, indicated for treatment of relapsing forms of multiple sclerosis, had annual US sales of US$3.8 billion as per IQVIA ...
-
September 25, 2020, Friday
Cipla gets final approval from USFDA for multiple sclerosis drug
Drug major Cipla on Friday said it has received final approval from the US health regulator for Dimethyl Fumarate capsules, ...
-
September 18, 2020, Friday
New Covid-19 drugs provide additional fuel as Cipla fires on all cylinders
Firm domestic sales and positive outlook in the US point to robust earnings
-
September 18, 2020, Friday
BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs
Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE
